MOUNTAIN VALLEY MD HOLDINGS INC. (via TheNewswire)
Ivermectinisan antiparasitic drugthat is administered to billions oflivestock and companion animalsannually and tohumansto treatvarious parasitic infestationsincluding development of broader applications forthe control of malaria.According tothe
"Just in the animal health sector alone, ivermectin has been classified as a'Blockbuster' drugfor 20 years,achievingsales in excess of
According to the
"Management at
Ivermectin is aBCS Class IIa drug, with poor water solubility, poor absorption and highly variable oral bioavailability,and as such, the Company believesis an ideal candidate for useinpreclinicaltrialsto generate data that demonstrate theefficacyofthe Quicksome(TM) technology to boost bioavailability andbio efficacy. The pre-clinical canine model studies were designed to prove both oral and sublingual superiority of the Quicksome(TM) formulations versus a commercial oral formulation tablet. The studies will examinemaximumplasmaconcentration (Cmax),Time of Maximum concentration observed(Tmax), andArea Under the Curve(AUC) tomeasure time-based drug concentrations in the bloodstreamfor boththe Quicksome(TM) ivermectin doseand the commercially available form toallowfordirect comparisons.
"We believe there are countless drugs whose absorption profiles can be vastly improved throughour Quicksome(TM)technology without the need for traditionalPhase One through Phase Three studies," continued Hancock."Our objective is to target the multiple billions of dollars of drugs currently in use and approved globallyand work with pharmaceutical partners toreformulate for improved efficacy and onset withour Quicksome(TM)technology."
Referenced sources
* FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2in vitro
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/
**
https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections
*** Antiparasitic drug market data sourcehttps://www.coherentmarketinsights.com/market-insight/antiparasitic-drugs-market-3782
ABOUT
MVMD's proposition for delivering Quicksome(TM) formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company's success across key health and wellness categories. Consistent with its vision towards "Helping People Live Their Best Life", MVMD applies its Quicksome(TM) technology to its ground-breaking work for the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
The Company's patented Quicksome(TM) desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is anew generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.
MVMD believes its health and wellness success will be bolstered further through Quicksome(TM) activation of cannabinoid molecules for pioneering medical cannabis applications. As such, MVMD also focuses on research and development, plant growth sciences and manufacturing across a portfolio of sustainable cannabis assets.
For more Company information and contact details, visitwww.mountainvalleymd.com.
SOURCE:
FORWARD-LOOKING INFORMATION DISCLAIMER
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company is making forward-looking statements, including but not limited to with respect to the ability to apply the Company's Quicksome(TM) technology to ivermectin and other drug delivery methods, and related matters, including but not limited to related trials and the potential success, results and impact of such applications. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
For further information:
President and Chief Executive Officer
Telephone: 647-725-9755
Email: dennis@mountainvalleymd.com
www.mountainvalleymd.com
Copyright (c) 2020 TheNewswire - All rights reserved.
Copyright (c) 2020 TheNewswire - All rights reserved., source
